bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
169 hedge funds and large institutions have $2.74B invested in bluebird bio in 2014 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 11 closing their positions.
436% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 11
224% more capital invested
Capital invested by funds: $845M → $2.74B (+$1.9B)
198% more call options, than puts
Call options by funds: $43.4M | Put options by funds: $14.5M
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
37% more funds holding
Funds holding: 123 → 169 (+46)
26% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$42.2M |
| 2 |
O
OppenheimerFunds
New York
|
+$38.8M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$24.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.4M |
| 2 |
DM
Deerfield Management
New York
|
-$21M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 4 |
QF
QVT Financial
New York
|
-$10.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$10.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
176
TFS Capital
West Chester,
Pennsylvania
| – | -$802K | -1,725 | Closed |
|
177
Jane Street
New York
| – | -$707K | -1,522 | Closed |
|
|
JRP
178
Jasper Ridge Partners
Menlo Park,
California
| – | -$512K | -1,101 | Closed |
|
179
BNP Paribas Financial Markets
Paris,
France
| – | -$45.9K | -99 | Closed |
|
|
PTC
180
Private Trust Company
Cleveland,
Ohio
| – | -$1K | -2 | Closed |
|
BLUE Hedge Fund Activity: Q4 2014 in Review
169 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2014, worth a combined $2.74B — up 224% from $845M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BLUE positions and 11 closed out — a net gain of 48 holders — while 53 added to existing stakes and 42 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $42.2M. The largest seller was Point72 Asset Management, cutting an estimated $28.4M.
- 169 institutional investors held bluebird bio (BLUE) as of Q4 2014, up from 123 in Q3 2014.
- Funds reported $2.74B of bluebird bio stock for Q4 2014, up 224% quarter-over-quarter.
- 59 funds opened new bluebird bio positions in Q4 2014 and 11 closed out, a net change of +48 holders.
- The largest bluebird bio buyer in Q4 2014 was Capital World Investors, an estimated $42.2M added.
- The largest bluebird bio seller in Q4 2014 was Point72 Asset Management, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2014.